Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Chidamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NMPA Approves Chidamide+R-CHOP For Diffuse Large B-Cell Lymphoma
    NMPA Approves Chidamide+R-CHOP For Diffuse Large B-Cell Lymphoma

    30 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/national-medical-products-administration-nmpa-approves-chipscreen-biosciences-chidamide-epidaza-combined-with-r-chop-for-the-treatment-of-diffuse-large-b-cell-lymphoma-302131654.html

    PR NEWSWIRE
    30 Apr 2024
    Share Share
    Clinical Results of ASC22 in Combination with Chidamide Presented at 12th IAS
    Clinical Results of ASC22 in Combination with Chidamide Presented at 12th IAS

    24 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-results-of-asc22-envafolimab-in-combination-with-chidamide-for-functional-cure-of-hiv-infection-presented-at-the-12th-ias-conference-on-hiv-science-301884101.html

    PR NEWSWIRE
    24 Jul 2023
    Share Share
    SPHCC Completed 1st Patient Dosing in Study of PD-L1 Antibody ASC22 + Chidamide
    SPHCC Completed 1st Patient Dosing in Study of PD-L1 Antibody ASC22 + Chidamide

    04 Jul 2022

    // ASIAONE

    https://www.asiaone.com/business/shanghai-public-health-clinical-center-completed-first-patient-dosing-clinical-study-pd-l1

    ASIAONE
    04 Jul 2022
    Share Share
    SPHCC Initiated Study of Envafolimab + Chidamide in HIV
    SPHCC Initiated Study of Envafolimab + Chidamide in HIV

    14 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/shanghai-public-health-clinical-center-initiated-functional-cure-study-of-anti-pd-l1-antibody-asc22-envafolimab-in-combination-with-chidamide-in-hiv-infected-patients-301481425.html

    PRNEWSWIRE
    14 Feb 2022
    Share Share
    United BioPharma Received IND Approvals from Taiwan FDA and China NMPA
    United BioPharma Received IND Approvals from Taiwan FDA and China NMPA

    18 Aug 2021

    // PRESS RELEASE

    http://unitedbiomedical.org/?p=25301

    PRESS RELEASE
    18 Aug 2021
    Share Share
    NMPA Approves Chipscreen Bioscience's Chidamide for Breast Cancer Indication
    NMPA Approves Chipscreen Bioscience's Chidamide for Breast Cancer Indication

    30 Nov 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/national-medical-products-administration-nmpa-approves-chipscreen-biosciences-chidamide-epidaza-for-breast-cancer-indication-300966800.html

    PR NEWSWIRE
    30 Nov 2019
    Share Share